The FY2025 (Dec) proxy of UroGen Pharma names 18 peer companies for pay. Among UroGen Pharma and these peers, CEO pay was 6th highest of 7 and total shareholder return was the highest of 6.
6th highest of 7in UroGen Pharma and its pay peers, FY2025 (Dec) by CEO pay:
$2.8M$9.7M
1st highest of 6in UroGen Pharma and its pay peers, FY2025 (Dec) by total shareholder return:
$14$264
Pay peer group, FY2025 (Dec) proxy
| Arcus Biosciences | ||
| IDEAYA Biosciences | ||
| Arvinas | ||
| Kura Oncology | ||
| Rigel Pharmaceuticals | ||
| Tango Therapeutics | Not disclosed | |
| Acrivon Therapeutics | Not disclosed | Not disclosed |
| Aura Biosciences | Not disclosed | Not disclosed |
| C4 Therapeutics | Not disclosed | Not disclosed |
| Day One Biopharmaceuticals | Not disclosed | Not disclosed |
| Erasca | Not disclosed | Not disclosed |
| Olema Pharmaceuticals | Not disclosed | Not disclosed |
| Sutro Biopharma | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
| Tyra Biosciences | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
| Y-mAbs Therapeutics | Not disclosed | Not disclosed |
| iTeos Therapeutics | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.